COMPASS Pathways Plc CMPS

Healthcare Biotechnology

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

NDAQ:CMPS - Post by User

COMPASS Pathways Plc

<< Previous

Bullboard Posts

Next >>

Post by PsilocybinAlphaon Dec 13, 2020 4:15pm

84 Views

Post# 32096302

Interview: Lars Wilde, Co-founder of COMPASS Pathways

We spoke to Lars Wilde, President, Chief Business Officer and Co-founder of COMPASS. We pressed Wilde on how the company will remain competitive in the context of its nonprofit peers such as the Usona Institute, and against the backdrop of increasing decriminalisation and legalisation of psychedelics (and associated therapy) that does not rely on regulatory approval.

Full interview here.

<< Previous

Bullboard Posts

Next >>

A&W will expand Pret A Manger brand across Canada